Oculis yields positive results in phase 2 study

Oculis yields positive results in phase 2 study

11.2.2020 – Oculis, a clinical-stage biopharmaceutical company developing novel topical treatments (eye drops) for ophthalmic diseases has obtained positive data from a phase 2 study of OCS-01, a novel eye drop formulation of dexamethasone, in development for the treatment of diabetic macular edema (DME).

read more on startupticker